Sleep Medicine
Volume 7, Issue 4 , Pages 340-349 , June 2006

The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting

  • Linda Abetz

      Affiliations

    • Mapi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UK
    • Corresponding Author InformationCorresponding author.
    • ,
  • Robert Arbuckle

      Affiliations

    • Mapi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UK
    • ,
  • Richard P. Allen

      Affiliations

    • Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
    • ,
  • Diego Garcia-Borreguero

      Affiliations

    • Fundación Jiménez Diaz, Madrid, Spain
    • ,
  • Wayne Hening

      Affiliations

    • UMDNJ-RW Johnson Medical School, New Brunswick, NJ, USA
    • ,
  • Arthur S. Walters

      Affiliations

    • The New Jersey Neuroscience Institute at JFK Medical Center, Seton Hall University School of Graduate Medical Education, Edison, NJ, USA
    • ,
  • Elena Mavraki

      Affiliations

    • GlaxoSmithKline, Greenford, UK
    • ,
  • Jeffrey M. Kirsch

      Affiliations

    • GlaxoSmithKline, Greenford, UK

Received 24 June 2005 ,Revised 27 December 2005 ,Accepted 29 December 2005.

References 

  1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome diagnosis and epidemiology workshop at the national institutes of health; international restless legs syndrome study group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–119
  2. Allen RP, Walters AS, Montplaisir J, et al. Restless Legs Syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165:1286–1292
  3. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18:128–147
  4. Earley CP. Restless legs syndrome. N Engl J Med. 2003;348:2103–2109
  5. Hening WA. Subjective and objective criteria in the diagnosis of the restless legs syndrome. Sleep Med. 2004;5:285–292
  6. Desautels A, Turecki G, Montplaisir J, et al. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet. 2001;69:1266–1270
  7. Chen S, Ondo WG, Rao S, et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet. 2004;74:876–885
  8. Bonati MT, Ferini-Strambi L, Aridon P, et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain. 2003;126(Pt 6):1485–1492
  9. Winkelmann J, Prager M, Lieb R, et al. ‘Anxietas Tibiarum’: depression and anxiety disorders in patients with restless legs syndrome. J Neurol. 2005;252:67–71
  10. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther. 2004;26:925–935
  11. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology. 2000;41:181–189
  12. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in Augsburg elderly. Neurology. 2000;54:1064–1068
  13. Allen R, Kirsch J, Abetz L, Washburn T. The impact of restless legs syndrome (RLS) on sleep and cognitive functioning. Eur J Neurol. 2002;9(Suppl. 2):50;[SC334]
  14. Allen RP, Earley CJ. Validation of the Johns Hopkins Restless Legs Severity Scale (JHRLSS). Sleep Med. 2001;2:239–242
  15. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group Rating Scale for restless legs syndrome. Sleep Med. 2003;4:121–132
  16. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12-week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75:92–97
  17. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome: TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;(19):1414–1423
  18. Allen RP, Kushida CA, Atkinson MJ. RLS QoL Consortium. Factor analysis of the International Restless Legs Syndrome Study Group's scale for restless legs severity. Sleep Med. 2003;4:133–135
  19. In:  Guy W editors. Clinical global impression (CGI). ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976;p. 218–222
  20. Hays RD, Stewart AL. Sleep measures. In:  Stewart AL,  Ware JE editor. Measuring functioning and well-being. The medical outcomes study approach. Durham: Duke University Press; 1992;p. 235–259
  21. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study sleep measure. Sleep Med. 2005;6:41–44
  22. Abetz L, Arbuckle R, Allen R, et al. Validating the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial patient population. Value Health. 2004;7(6):793
  23. Abetz L, Vallow S, Kirsch J, et al. Validation of the restless legs syndrome quality of life questionnaire. Value Health. 2005;8:157–167
  24. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(3 Suppl.):178–189
  25. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Earlbaum Associates; 1988;
  26. Guyatt GH, Osaba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371–383
  27. Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med. 2004;5:485–488
  28. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J. 1999;14:1038–1043
  29. Campbell DT, Fiske DW. Convergent and discriminant validation by the Multi-trait Multi-method Matrix. Psychol Bull. 1959;56:81–105
  30. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334
  31. Nunnally JC. Psychometric theory. 2nd ed. New York: McGraw-Hill; 1978;
  32. Hays RD, Anderson R, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In:  Staquet M,  Hays R,  Fayers PM editor. Quality of life assessment in clinical trials. Methods and practice. Oxford: Oxford University Press; 1998;

PII: S1389-9457(06)00006-2

doi: 10.1016/j.sleep.2005.12.011

Sleep Medicine
Volume 7, Issue 4 , Pages 340-349 , June 2006

Article Tools

* Image Usage & Resolution